Viking Therapeutics (VKTX) Stock Forecast & Price Target

Viking Therapeutics Inc. has made significant advancements in its clinical programs, particularly with VK2735, which demonstrates substantial weight loss efficacy compared to competitors in the obesity treatment market. The company's strategic agreement with CordenPharma to secure large-scale production capacity further strengthens its competitive position, ensuring efficient manufacturing and distribution as it prepares for market entry. Additionally, with the potential for total addressable market (TAM) expansion into areas such as Alzheimer's and hypertension, Viking's pipeline continues to show promise for long-term value creation.

Viking Therapeutics Inc's outlook is negatively impacted by an increase in research and development spending, resulting in a downward adjustment of its financial projections. The potential for negative safety or efficacy results in late-stage clinical trials poses a significant risk, as such outcomes could further reduce projected sales revenue and overall market penetration of its drug candidates. Additionally, concerns over the company's ability to secure adequate funding for ongoing development, compounded by disappointing earnings performance and market apprehension regarding clinical outcomes, heighten the risk associated with its stock.